immatics Biotechnologies GmbH   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Tuebingen United States (2000)

Organization Overview

First Clinical Trial
2007
NCT00523159
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

immatics biotechnolgies GmbH | immatics Biotechnologies GmbH | Immatics US, Inc.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 3)

Carcinoma, Hepatocellular (Phase 2)

Carcinoma, Merkel Cell (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 1)

Carcinoma, Renal Cell (Phase 3)

Carcinoma, Squamous Cell (Phase 1)

Central Nervous System Neoplasms (Phase 2)

Colorectal Neoplasms (Phase 2)

Glioblastoma (Phase 2)

Lung Neoplasms (Phase 1)

Nervous System Neoplasms (Phase 1)

Recurrence (Phase 1)

Squamous Cell Carcinoma of Head and Neck (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 16
  • # of Trial APIs: 23